Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.
about
The challenge of developmental therapeutics for adrenocortical carcinomaHuman adrenocortical carcinoma cell lines.Therapy of adrenocortical cancer: present and future.Current and emerging therapies for advanced adrenocortical carcinoma.Bone Targeted Therapies for Bone Metastasis in Breast CancerCurrent management options for recurrent adrenocortical carcinoma.Outcomes after resection of cortisol-secreting adrenocortical carcinomaNovel targeted therapies in adrenocortical carcinoma.Adrenocortical carcinoma: past, present, and future.Management of adjuvant mitotane therapy following resection of adrenal cancer.The use of mass spectrometry to improve the diagnosis and the management of the HPA axis.Recent developments in drug therapy for Cushing's disease.Management of adrenal cancer: a 2013 update.Aldosterone-secreting adrenal cortical carcinoma. A case report and review of the literature.Cushing's syndrome: an update on current pharmacotherapy and future directions.Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE).Proteome analysis of adrenal cortical tumors.Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro.Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells.Potent antitumor activity of HSP90 inhibitor AUY922 in adrenocortical carcinoma.Repeated resections for liver metastasis from primary adrenocortical carcinoma: A case report.Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma.Resection of adrenocortical carcinoma liver metastasis: is it justified?Significance of heparanase-1 and vascular endothelial growth factor in adrenocortical carcinoma angiogenesis: potential for therapy.CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells.Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis.
P2860
Q28072970-1D036F0E-A7D4-4823-BA89-32B31C133940Q34216956-C0038014-5066-417F-8A87-45738768BE94Q35232257-C8B58CBE-C7A4-4A22-BA7F-081EC9CA10F1Q35584305-AE48FA34-0634-4E5C-9A21-B66BE1EE7ED7Q35750448-7C0F940F-B5EC-49D0-B48F-68234B005265Q36925876-4EA2D183-329E-44B3-A3DD-2A51F12EEC1DQ37119591-63F1792C-9B44-4CB8-9AAF-79C7C86E3ED0Q37233378-4B569312-B3C5-4A5B-9A31-6F36029F48FAQ37999696-8022D2CF-9AA2-4453-AA2E-E40C8A71C49EQ38019388-0E9E211D-3716-4312-889A-57FF981AF200Q38089640-F9A2956F-2E1D-4C66-8219-D1F32E5F96D3Q38112082-79F28413-3C9F-4AF8-85E2-34B90DCEF7ABQ38181425-217C80AD-4684-4394-A2BD-F8B7DF3556D8Q38200547-8DA3DE94-3510-46DF-A05B-0E835DACE4DCQ38541695-C6BDC9D8-8E88-47A9-9A25-8C64A09140A2Q38545507-B640F4F1-4893-47D8-AA1D-906E27A91CCFQ38888303-F4FB22AE-EF95-4D75-8329-0EABEA4DE744Q38925278-EFF74840-B4B8-4BDB-A7D6-385EFB8B9E4AQ38968381-5C6FABA7-51A4-4E4B-AF7E-EC44B34F2668Q38992870-77825C4D-3BB0-4789-93D5-D3AC133AD886Q39479211-01DF0B77-EB00-4144-98D7-12B159FAA3E8Q50091898-87F66352-8B77-46CF-943F-9EBF8E7469CDQ54313412-C29733E0-514B-4371-98ED-18CE4E6249EEQ54578853-40F85520-E527-4EFE-ABDD-DE06493E7DD5Q55091442-984048F0-FEEE-49B6-8E9B-689E10C5AE32Q55399185-B73AAC59-F54A-49B8-9077-B384B048F1A8
P2860
Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Management of endocrine manife ...... for adrenocortical carcinoma.
@en
Management of endocrine manife ...... for adrenocortical carcinoma.
@nl
type
label
Management of endocrine manife ...... for adrenocortical carcinoma.
@en
Management of endocrine manife ...... for adrenocortical carcinoma.
@nl
prefLabel
Management of endocrine manife ...... for adrenocortical carcinoma.
@en
Management of endocrine manife ...... for adrenocortical carcinoma.
@nl
P2093
P2860
P356
P1476
Management of endocrine manife ...... for adrenocortical carcinoma.
@en
P2093
Irina Veytsman
Lynnette Nieman
P2860
P304
P356
10.1200/JCO.2008.17.2775
P407
P577
2009-08-10T00:00:00Z